Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 2:64:8-15.
doi: 10.1016/j.ejvsvf.2025.01.005. eCollection 2025.

Strategies for Antithrombotic Management During Non-cardiac Arterial Procedures: Results of the International ACTION Survey

Max Hoebink  1   2   3 , Vincent Jongkind  1   2   3 ; European Vascular Research Collaborative; ACTION-1 Research Collaborative
Collaborators, Affiliations

Strategies for Antithrombotic Management During Non-cardiac Arterial Procedures: Results of the International ACTION Survey

Max Hoebink et al. EJVES Vasc Forum. .

Abstract

Objective: Peri-procedural antithrombotics are used extensively to prevent thromboembolic complications during non-cardiac arterial procedures (NCAP) worldwide. However, there is a lack of evidence to support recommendations on antithrombotic strategies, possibly leading to substantial variation in local practices. A comprehensive overview of antithrombotic strategies is needed to identify the most widely accepted protocols employed during NCAP, highlight variations in local practices, and identify new research targets to establish evidence based peri-procedural anticoagulation management.

Methods: An international, web based survey study was conducted from March to October 2023, targeting vascular clinical specialists who applied antithrombotic strategies during NCAP in daily practice.

Results: The survey was completed by 436 vascular clinical specialists from 45 countries (Europeans: 93%, vascular surgeons or vascular surgery residents: 98%). Systemic unfractionated heparin was used by nearly all vascular specialists during all procedures (varying between 98-99%, depending on the procedure type), but could vary depending on specific NCAP. A fixed starting dose (39-52%, most often 5 000 IU [80-89%]) or an actual bodyweight dependent dose (42-52%, most commonly 100 IU/kg [40-67%] or 50 IU/kg [17-40%]) was mainly used. Except during fenestrated or branched endovascular aneurysm repair procedures (51%), activated clotting time (ACT) was employed by a minority (26-31%). A large variety in measurement protocols was observed, yet a target ACT of 200 seconds was most often used for all NCAP types (44-54%). Most vascular specialists considered a heparin follow up dose (61-81%) and heparin reversal using protamine (54-63%), both for a variety of indications. Of the participants, 68% expressed discontent with their current antithrombotic protocol(s).

Conclusion: This comprehensive, international survey study revealed large variation among vascular clinical specialists' heparinisation strategies during NCAP. Together with the considerable discontent expressed regarding protocols, this emphasises the urgent need for comparative, randomised studies on antithrombotic management during NCAP.

Keywords: Activated clotting time; Antithrombotic strategies; Heparin; Non-cardiac arterial procedures; Protamine; Vascular surgery.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Roosendaal L.C., Hoebink M., Wiersema A.M., Yeung K.K., Blankensteijn J.D., Jongkind V., et al. Perprocedural heparinization in non-cardiac arterial procedures: the current practice in The Netherlands. J Endovasc Ther. 2023 doi: 10.1177/15266028231199714. [Epub ahead of print]. - DOI - PMC - PubMed
    1. Thompson J.F., Mullee M.A., Bell P.R., Campbell W.B., Chant A.D., Darke S.G., et al. Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a Joint Vascular Research Group study. Eur J Vasc Endovasc Surg. 1996;12:86–90. - PubMed
    1. Duschek N., Vafaie M., Skrinjar E., Hirsch K., Waldhör T., Hübl W., et al. Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial. J Thromb Haemost. 2011;9:2159–2167. - PubMed
    1. Doganer O., Jongkind V., Blankensteijn J.D., Yeung K.K., Wiersema A.M. A standardized bolus of 5 000 IU of heparin does not lead to adequate heparinization during non-cardiac arterial procedures. Ann Vasc Surg. 2021;71:280–287. - PubMed
    1. Roosendaal L.C., Wiersema A.M., Smit J.W., Doganer O., Blankensteijn J.D., Jongkind V. Editor's Choice – sex differences in response to administration of heparin during non-cardiac arterial procedures. Eur J Vasc Endovasc Surg. 2022;64:557–565. - PubMed

LinkOut - more resources